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Recombinant human growth hormone (r-hGH) is indi-
cated for pediatric patients with a variety of growth
disorders. Until recently, analysis of adherence to treat-
ment has been limited by recall bias and reliance on
self-reporting. Accurate recorded data on r-hGH use
can now be collected using the easypod™ auto-injector.
The multinational easypod™ connect observational
study (ECOS) was launched in 2010 to collect and
analyze r-hGH dosing, clinical and auxological data
from patients prescribed r-hGH via easypod™. Twelve
countries are currently recruiting patients.
The primary objective is to assess adherence in patients
receiving r-hGH via easypod™. Secondary objectives
include describing the impact of adherence on clinical out-
comes and identifying adherence patterns.
Data will be obtained from patients’ medical notes and
uploaded from auto-injectors. Auxological parameters are
collected, and prescribed dosing data recorded at clinic
visits as per routine clinical practice. Annual adherence
will be calculated (number of days the patient adminis-
tered injections divided by the expected number of injec-
tion days over 1 year, as a percentage). Dose intensity
(total amount of dose received divided by planned amount
of dose over 1 year, as a percentage) will be analyzed.
Adherence data will be correlated with clinical outcomes.
An adherence pattern will also be developed based on
patients’ age, sex, indication, self-injection, and time on
treatment. The study will run until 2015, with yearly ana-
lyses, and will be overseen by a multinational scientific
steering committee.
With data from ECOS, it will be possible to accurately
assess r-hGH treatment adherence in various growth
disorders and explore its potential impact on growth.
Ultimately, drivers of and barriers to treatment adherence
will be identified, allowing appropriate support programs
to be developed.
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